<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124212</url>
  </required_header>
  <id_info>
    <org_study_id>2016-02052</org_study_id>
    <nct_id>NCT03124212</nct_id>
  </id_info>
  <brief_title>Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland</brief_title>
  <acronym>CASCADE</acronym>
  <official_title>Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Basel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Basel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast, colorectal, ovarian, and endometrial cancers constitute approximately 30% of newly
      diagnosed cancer cases in Switzerland and affect more than 12,000 individuals annually.
      Several hundred of these patients are likely to carry known genetic mutations associated with
      HBOC or LS. Genetic testing for hereditary susceptibility to cancer can prevent many cancer
      deaths through early identification and engagement in high-risk management care that involves
      intensive surveillance, chemoprevention and/or prophylactic surgery. However, current rates
      of genetic testing indicate that many Swiss mutation carriers and their family members do not
      use cancer genetic services (counseling and/or testing), either due to lack of coordination
      of care or due to lack of communication about the mutation among family members.

      Cascade screening identifies and tests family members of a known mutation carrier. It
      determines whether asymptomatic family members are carriers of the identified mutation and
      proposes management options to reduce harmful outcomes. Robust evidence of basic science and
      descriptive population-based studies in Switzerland support the necessity of cascade
      screening for HBOC and LS. However, translation of this knowledge into public health
      interventions is lacking.

      Specific Aims of the CASCADE study are:

        1. Survey Index Patients diagnosed with HBOC or LS from clinic-based genetic testing
           records and determine their cancer status and surveillance practices; needs for
           coordination of medical care; psychosocial needs; patient-provider and patient-family
           communication needs; quality of life; willingness to serve as advocates for cancer
           genetic services for blood relatives.

        2. Survey first- and second-degree relatives, and first cousins identified from pedigrees
           and/or family history records of HBOC and LS Index Patients and determine their cancer
           and mutation status; cancer surveillance practices; needs for coordination of medical
           care; barriers and facilitators to using cancer genetic services; psychosocial needs;
           patient-provider and patient-family communication needs; quality of life; willingness to
           participate in a study designed to increase use of cancer genetic services.

        3. Explore the influence of patient-provider communication about genetic cancer risk on
           patient-family communication and the acceptability of a family-based communication,
           coping, and decision support intervention with focus group(s) of mutation carriers and
           blood relatives.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please see study protocol provided in the references
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establishing the CASCADE Cohort</measure>
    <time_frame>12 months</time_frame>
    <description>Response rate for Index Patients with HBOC and LS and blood relatives</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer Surveillance</measure>
    <time_frame>12 months</time_frame>
    <description>Number of mammograms, CBEs and MRIs of Index Patients and Blood Relatives</description>
  </secondary_outcome>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Hereditary Breast and Ovarian Cancer</condition>
  <condition>Lynch Syndrome</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CASCADE genetic screening</intervention_name>
    <description>Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Living carriers of pathogenic mutations associated with HBOC and LS, and their blood
        relatives (first- and second-degree, and first cousins)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Carrier of a mutation associated with HBOC or LS

          2. Have at least one living blood relative

          3. Men and women

          4. 18 years old and older

          5. Mentally and physically able to provide informed consent

          6. Can read and speak German or French or Italian or English

          7. Currently living in Switzerland.

        Exclusion Criteria:

          1. Carriers of unclassified variants (VUS) in BRCA1, BRCA2 or MLH1, MSH2, MSH6, PMS2,
             EPCAM genes

          2. Not living in Switzerland

          3. Patients who are critically ill and cannot complete the CASCADE survey

          4. Participants who are institutionalized (e.g., nursing homes) or incarcerated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria C Katapodi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria C Katapodi, PhD</last_name>
    <phone>++41791095163</phone>
    <email>maria.katapodi@unibas.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Heinimann, PhD</last_name>
      <phone>++41612653654</phone>
      <email>Karl.Heinimann@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Burki, MD</last_name>
      <phone>++41615565883</phone>
      <email>nicole.buerki@aeschenpraxis.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Viola Heinzelmann-Schwarz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karl Heinimann, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Burki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Kurzeder, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Zvizzera Italiana</name>
      <address>
        <city>Bellinzona</city>
        <zip>6962</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivia Pagani, MD</last_name>
      <phone>++918118435</phone>
      <email>olivia.pagani@eoc.ch</email>
    </contact>
    <contact_backup>
      <last_name>Rossella Graffeo, MD</last_name>
      <phone>++918118435</phone>
      <email>Rossella.GraffeoGalbiati@eoc.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Olivia Pagani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rossella Graffeo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bauch- und Tumorzentrum der Universitatsklinik fur Viszerale Chirurgie und Medicine, Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>2010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik C Horvath, PhD</last_name>
      <phone>++41316325900</phone>
      <email>Henrik.Horvath@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Henrik C Horvath, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatklinik fur Medizinische Onkologie, Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuela Rabaglio, MD</last_name>
      <phone>++41316324370</phone>
      <email>Manuela.Rabaglio@insel.ch</email>
    </contact>
    <contact_backup>
      <last_name>Rosmarie Buhrer, MSN</last_name>
      <phone>++41316325944</phone>
      <email>Rosmarie.Buehrer@insel.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Manuela Rabaglio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unite d'Oncogenetique et de Prevention des Cancers</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Chappuis, MD, PhD</last_name>
      <phone>++41223729853</phone>
      <email>Pierre.Chappuis@hcuge.ch</email>
    </contact>
    <contact_backup>
      <last_name>Valeria Viassolo, MD</last_name>
      <phone>++41223729853</phone>
      <email>Valeria.Viassolo@hcuge.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre O Chappuis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valeria Viassolo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://swisscascade.ch/en/</url>
    <description>CASCADE website</description>
  </link>
  <reference>
    <citation>Katapodi MC, Viassolo V, Caiata-Zufferey M, Nikolaidis C, Bührer-Landolt R, Buerki N, Graffeo R, Horváth HC, Kurzeder C, Rabaglio M, Scharfe M, Urech C, Erlanger TE, Probst-Hensch N, Heinimann K, Heinzelmann-Schwarz V, Pagani O, Chappuis PO. Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol. JMIR Res Protoc. 2017 Sep 20;6(9):e184. doi: 10.2196/resprot.8138.</citation>
    <PMID>28931501</PMID>
  </reference>
  <reference>
    <citation>Nikolaidis C, Ming C, Pedrazzani C, van der Horst T, Kaiser-Grolimund A, Ademi Z, Bührer-Landolt R, Bürki N, Caiata-Zufferey M, Champion V, Chappuis PO, Kohler C, Erlanger TE, Graffeo R, Hampel H, Heinimann K, Heinzelmann-Schwarz V, Kurzeder C, Monnerat C, Northouse LL, Pagani O, Probst-Hensch N, Rabaglio M, Schoenau E, Sijbrands EJG, Taborelli M, Urech C, Viassolo V, Wieser S, Katapodi MC; for the CASCADE Consortium. Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop. Public Health Genomics. 2018;21(3-4):121-132. doi: 10.1159/000496495. Epub 2019 Jan 29.</citation>
    <PMID>30695780</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Basel</investigator_affiliation>
    <investigator_full_name>Maria Katapodi</investigator_full_name>
    <investigator_title>Professor of Nursing Science</investigator_title>
  </responsible_party>
  <keyword>mutation carrier</keyword>
  <keyword>blood relative</keyword>
  <keyword>genetic testing</keyword>
  <keyword>family-based cohort</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Colorectal Neoplasms, Hereditary Nonpolyposis</mesh_term>
    <mesh_term>Hereditary Breast and Ovarian Cancer Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Upon request, including purpose and expected timeline, anonymized patient data will be shared</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>January 2024- December 2029</ipd_time_frame>
    <ipd_access_criteria>Upon request - TBD</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

